Yale Researchers Develop RNA-Based Therapy That Can Protect From Range of COVID-19 Variants

SLR14 Reduces Pneumonia COVID

Compared with a control (left), treatment with SLR14 (right) reduces the signs of inflammation and pneumonia in the lungs of SARS-CoV-2–infected mice. Credit: ©2021 Mao et al. Originally published in Journal of Experimental Medicine. https://doi.org/10.1084/jem.20211818

Researchers at Yale School of Medicine have discovered that an RNA molecule that stimulates the body’s early antiviral defense system can protect mice from a range of emerging SARS-CoV-2 variants. The study, published recently in the Journal of Experimental Medicine (JEM), could lead to new treatments for COVID-19 in immunocompromised patients, as well as providing an inexpensive therapeutic option for developing countries that currently lack access to vaccines.

Though approved vaccines against SARS-CoV-2 are highly effective at preventing severe disease and death during the ongoing COVID-19 pandemic, vaccine availability is extremely limited in many low-income countries, and new, vaccine-resistant strains of the virus could emerge in the future. Moreover, the vaccines’ effectiveness is already reduced in immunocompromised individuals unable to form sufficient numbers of antibodies or T cells that specifically target the viral spike protein. These individuals are susceptible to chronic, long-term SARS-CoV-2 infections.

“This is why, in addition to the use of vaccines in preventing COVID-19, efforts are required to develop efficacious therapeutics against SARS-CoV-2,” says Akiko Iwasaki, a professor at Yale School of Medicine.

The body’s first line of defense against SARS-CoV-2—before the involvement of antibodies and T cells—is thought to depend on receptor molecules such as RIG-I that recognize the virus’s genetic material and induce the production of signaling proteins known as type I interferons. These interferons, in turn, promote the production of proteins that can inhibit viral replication and stimulate the recruitment of immune cells to fight the infection.

Multiple studies have suggested that early and robust production of interferons protects against COVID-19, whereas delayed production is associated with severe disease. A clinical trial has shown that treating COVID-19 patients with purified interferon protein early during disease can reduce mortality, but manufacturing interferons is extremely expensive.

In the new JEM study, Iwasaki and colleagues suggest a cheaper alternative: treating patients with short RNA molecules that mimic SARS-CoV-2’s genetic material and activate the RIG-I receptor to stimulate production of type I interferons by the body’s own cells.

The researchers tested their approach in mice susceptible to SARS-CoV-2 infection. A single dose of an RNA molecule named SLR14 was sufficient to protect the mice from severe disease and death, particularly if the treatment was provided shortly before or soon after exposure to the virus. When administered shortly after viral infection, SLR14 was more effective than treating mice with purified interferon protein, the researchers determined.

Crucially, SLR14 protected mice from all emerging SARS-CoV-2 variants, including the delta variant responsible for the recent surge in US COVID-19 cases.

Finally, Iwasaki and colleagues tested SLR14 in immunocompromised Rag/ mice chronically infected with SARS-CoV-2. The RNA molecule was able to completely clear the virus from these animals, even though they lack both T cells and antibody-producing B cells.

Iwasaki and colleagues point out that RNA molecules like SLR14 are relatively cheap and easy to manufacture. “SLR14 therefore holds great promise as a new class of RNA therapeutics that can be applied as antivirals against SARS-CoV-2,” Iwasaki says. “Moreover, because this RNA-based therapeutic approach is simple and versatile, our study will facilitate pandemic preparedness and response against future respiratory pathogens sensitive to type I interferons.”

Reference: ” A stem-loop RNA RIG-I agonist protects against acute and chronic SARS-CoV-2 infection in mice” by Tianyang Mao, Benjamin Israelow, Carolina Lucas, Chantal B.F. Vogels, Maria Luisa Gomez-Calvo, Olga Fedorova, Mallery I. Breban, Bridget L. Menasche, Huiping Dong, Melissa Linehan, Yale SARS-CoV-2 Genome Surveillance Initiative, Craig B. Wilen, Marie L. Landry, Nathan D. Grubaugh, Anna M. Pyle and Akiko Iwasaki, 10 November 2021, Journal of Experimental Medicine (JEM).
DOI: 10.1084/jem.20211818

Note: This article have been indexed to our site. We do not claim legitimacy, ownership or copyright of any of the content above. To see the article at original source Click Here

Related Posts
Plan for Canada to Triple Population to 100 Million by 2100 thumbnail

Plan for Canada to Triple Population to 100 Million by 2100

Canada’ century Initiative calls for a bigger, bolder Canada with over 100 million people by 2100. Former Canadian Prime Minister Mulroney supports the new national policy that would commit to tripling Canada’s population by 2100. By 2026, Century Initiative says Canada should pin the annual immigration target to 1.25 percent of its population per year.…
Read More
FDA approves first MASH drug thumbnail

FDA approves first MASH drug

News in Brief Published: 17 April 2024 Nature Biotechnology volume 42, page 540 (2024)Cite this article 1350 Accesses 2 Altmetric Metrics details The first drug to treat fatty liver disease due to metabolic dysfunction-associated steatohepatitis (MASH) has been given a green light by the US Food and Drug Administration. Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) received an accelerated approval
Read More
Nasal Spray COVID Preventives Are Finally in Development thumbnail

Nasal Spray COVID Preventives Are Finally in Development

Different methods of drug delivery give us more tools to fight disease Credit: James Olstein Covid is credited with propelling clinical innovation. But for a disease that seems to start in people’s noses, none of the available drugs or vaccines are delivered intranasally. Killing the virus before it travels into our lower airways could prevent…
Read More
Delta 8 THC Reviews: 7 Best Top D8 THC Companies in 2022 thumbnail

Delta 8 THC Reviews: 7 Best Top D8 THC Companies in 2022

This article contains affiliate links to products. We may receive a commission for purchases made through these links.Year after year, the cannabis industry continues to grow both domestically and internationally. Did you know that there were over 200 million cannabis users in the world as of 2019? As the number of global cannabis product consumers…
Read More
Poppyseed-sized nuclear fuel cells might power a NASA moon base thumbnail

Poppyseed-sized nuclear fuel cells might power a NASA moon base

Nuclear fuel cells the size of poppy seeds could power NASA’s Artemis lunar base once it begins operations around 2030. Designed by researchers at Bangor University’s Nuclear Futures Institute in the UK, the miniscule power source—dubbed “Trisofuel”—is intended to run on a micro nuclear generator roughly the size of a small car created by Rolls
Read More
Protein from the liver can cause Alzheimer's disease in the brain thumbnail

Protein from the liver can cause Alzheimer's disease in the brain

סיכום: חלבוני עמילואיד–ביתא שנוצרו בכבד נישאים בזרם הדם ע"י ליפופרוטאינים אל המוח. הדבר גורם לנוירודגרדציה, ניוון מוחי ודלקת, מאפיינים נפוצים של מחלת אלצהיימר מקור: PLOS      עיבוד: גילת סיימון היפוקמפוס gyrus משונן בעכברי HSHA, המראה הפעלה משמעותית של אסטרוציטים (GFAP: לבן) ומתח חמצוני (8OHdG: ירוק) המקיפים את נימי המוח (laminin-a4: אדמדם). מכתים גרעינים עם DAPI (כחול).…
Read More
Index Of News
Total
0
Share